National Pension Service Has $230.30 Million Holdings in Bristol Myers Squibb Company $BMY

National Pension Service boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 5.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,106,519 shares of the biopharmaceutical company’s stock after acquiring an additional 244,970 shares during the quarter. National Pension Service owned 0.25% of Bristol Myers Squibb worth $230,304,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMY. Gateway Investment Advisers LLC grew its position in shares of Bristol Myers Squibb by 10.0% during the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after purchasing an additional 10,284 shares in the last quarter. CWA Asset Management Group LLC boosted its stake in Bristol Myers Squibb by 25.9% during the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after buying an additional 30,909 shares during the period. Commonwealth Retirement Investments LLC grew its position in Bristol Myers Squibb by 24.6% during the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock worth $2,740,000 after buying an additional 11,690 shares in the last quarter. Railway Pension Investments Ltd increased its stake in Bristol Myers Squibb by 3.7% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after acquiring an additional 40,300 shares during the last quarter. Finally, Stephens Inc. AR increased its stake in Bristol Myers Squibb by 13.5% in the 3rd quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after acquiring an additional 32,476 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $57.00 price target (up previously from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Truist Financial set a $65.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. Morgan Stanley restated an “underweight” rating and set a $37.00 price objective (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Finally, Citigroup reaffirmed a “neutral” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $57.43.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $55.03 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The stock has a market cap of $112.02 billion, a PE ratio of 18.59, a PEG ratio of 0.17 and a beta of 0.29. The company’s fifty day moving average is $53.41 and its 200 day moving average is $48.66. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The company’s revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.80 earnings per share. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be issued a $0.63 dividend. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 85.14%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.